Epoprostenol in Pulmonary Hypertensive Crisis

Mortality Benefit and Treatment Guidelines

The American College of Cardiology recommends intravenous epoprostenol as the treatment of choice for patients with pulmonary arterial hypertension experiencing acute decompensation or pulmonary hypertensive crisis, as it is the only PAH therapy proven to reduce mortality in randomized controlled trials 1, 2
In a landmark 12-week randomized controlled trial, 8 of 40 patients (20%) died in the conventional therapy group while zero deaths occurred in the epoprostenol group (p=0.003), demonstrating a significant mortality benefit 1, 2, 3
Long-term survival data demonstrates 1-year, 2-year, 3-year, and 5-year survival rates of 85%, 70%, 63%, and 55% respectively with epoprostenol, compared to predicted survival of 59%, 46%, and 35% without treatment, highlighting the importance of epoprostenol in improving survival outcomes 1, 4

The European Heart Journal recommends starting epoprostenol at 2-4 ng/kg/min and titrating rapidly based on clinical response and side effects, with a target dose for the first 2-4 weeks of typically 10-15 ng/kg/min 5, 6
Optimal long-term doses range between 20-40 ng/kg/min in most patients, though some require higher doses, and dose increases should be limited by side effects rather than arbitrary targets 5, 6

The American College of Cardiology suggests that concurrent management is essential while initiating epoprostenol, including administering diuretics for right ventricular failure and fluid retention, providing supplemental oxygen to maintain arterial saturation >90%, and considering inotropic support with dobutamina for hypotensive patients 7
Response at 3 months predicts long-term survival and should guide escalation decisions, with persistence of NYHA functional class III or IV at 3 months indicating poor prognosis and need for lung transplant evaluation 1, 4, 5

The Journal of the American College of Cardiology notes that epoprostenol improves exercise capacity and hemodynamics in PAH associated with scleroderma spectrum diseases, though survival benefit is less pronounced, and that rapid development of pulmonary edema after epoprostenol administration suggests pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis, which are contraindications 8, 9, 2